Prostate cancer chemotherapy: Emerging from the shadows

Journal of Clinical Oncology

Volumn 23, Issue 15, 2005, Pages 3302-3303

  Roth, Bruce J ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DRUG POTENTIATION; EDITORIAL; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AGED; CANCER INVASION; CANCER STAGING; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; MALE; MIDDLE AGED; MORTALITY; NOTE; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 20644442247     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.11.933     Document Type: Editorial

References (12)

1. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative endpoints. J Clin Oncol 14:1756-1764, 1996
2. Kantoff PW, Halabi S, Conoway M, et al: Hydrocortisone with or without mitoxantrone in with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17:2506-2513, 1999
3. Picus J, Schultz M: Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results. Semin Oncol 26:14-18, 1999 (suppl 17)
4. Beer TM, Pierce WC, Lowe BA, et al: Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12:1273-1279, 2001
5. Speicher LA, Barone L, Tew KD: Combined antimicrotubular activity of estramustine and Taxol in human prostatic carcinoma cell lines. Cancer Res 52:4433-4440, 1992
6. Petrylak DP, Macarthur RB, O'Connor J, et al: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17:958-967, 1999
7. Savarese DM, Halabi S, Hars V, et al: Phase II study of docetaxel, estramustine and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. J Clin Oncol 19:2509-2516, 2001
8. Sinibaldi VJ, Carducci MA, Moore-Cooper S, et al: Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen-independent prostate carcinoma. Cancer 94:1457-1465, 2002
9. Oudard S, Banu E, Beuzeboc P, et al: Multicenter randomized phase ii study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23:3343-3351, 2005
10. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
11. Petrylak DP, Tangen CM, Hussain MHA, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
12. Eymard J-C, Joly F, Priou F, et al: Phase II randomized trial of docetaxel + estramustine versus docetaxel alone in patients with hormone-refractory prostate cancer: A final report. Proc Am Soc Clin Oncol 23:406, 2004 (abstr 4603)